Wenjing Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Wenjing Li has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Changping Wu
Department of Tumor Biological Treatment, the Third Affiliated Hospital of Soochow University, Changzhou, China
1 shared publication Haijun Chen
Department of Otorhinolaryngology Head and Neck Surgery, the Third Affiliated Hospital of Soochow University (Changzhou First People’s Hospital)
1 shared publicationHaixiang Xue
Department of Otorhinolaryngology Head and Neck Surgery, the Third Affiliated Hospital of Soochow University (Changzhou First People’s Hospital)
1 shared publication- Haixiang Xue
Department of Otorhinolaryngology, The First People’s Hospital of Changzhou, The Third Affiliated Hospital of Soochow University, Soochow University, China
1 shared publication Jianqiang You
Department of Otorhinolaryngology Head and Neck Surgery, the Third Affiliated Hospital of Soochow University (Changzhou First People’s Hospital)
1 shared publication- Jianqiang You
Department of Otorhinolaryngology, The First People’s Hospital of Changzhou, The Third Affiliated Hospital of Soochow University, Soochow University, China
1 shared publication
Latest Publications
- Open Access
- 8 October 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1898263
HHLA2-KCTD12 axis: a potential mechanism regulating the biological functions of laryngeal squamous cell carcinoma
Background: Accumulating evidence suggests that aberrant HHLA2 expression is closely implicated not only in tumorigenesis, disease progression, and metastatic spread, but also in the intricate modulation of the tumor immune microenvironment. Nevertheless, the biological functions of HHLA2 and the molecular mechanisms underlying its action in laryngeal squamous cell carcinoma (LSCC) remain unexplored. Materials and methods: HHLA2 expression was systematically assessed in LSCC tumor specimens and matched adjacent tissues using multiplex immunofluorescence (mIHC). The functional consequences of HHLA2 silencing in LSCC cells were evaluated through a series of in vitro assays, including CCK-8–based proliferation analysis, wound-healing (scratch) assays, and invasion assays. Transcriptomic sequencing integrated with public database mining was subsequently performed to identify key target genes potentially governed by HHLA2 in regulating LSCC biological behavior. Furthermore, Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Set Enrichment Analysis (GSEA) pathway analyses were conducted to delineate the signaling networks and molecular pathways through which HHLA2 might exert its regulatory effects in LSCC. Results: HHLA2 expression was significantly elevated in LSCC tumor tissues, and associated with poor prognosis in patients. Functional experiments revealed that suppression of HHLA2 leads to marked inhibition of LSCC cell proliferation, migration, and invasion, underscoring its essential role in sustaining malignant phenotypes. Mechanistically, we identified potassium channel tetrameric domain 12 (KCTD12) as a pivotal target of HHLA2 in mediating these oncogenic processes. Importantly, forced overexpression of KCTD12 effectively counterbalanced the inhibitory effects induced by HHLA2 depletion, thereby restoring proliferative, migratory, and invasive potential to LSCC cells. Furthermore, pathway enrichment analyses indicated that the TNF—NF-κB signalling pathway might serve as a key conduit through which HHLA2 orchestrated both tumor cell functions and immune regulatory mechanisms. The HHLA2-KCTD12 axis may regulate the phenotype of LSCC cells and reshape the tumor immune microenvironment through the TNF—NF-κB signaling pathway. Conclusions: HHLA2 enhanced the proliferative, migratory, and invasive capacities of LSCC cells and might contribute to immune microenvironment remodeling via modulation of TNF—NF-κB signaling through the HHLA2–KCTD12 axis.
- 8 October 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1898263
Open AccessHHLA2-KCTD12 axis: a potential mechanism regulating the biological functions of laryngeal squamous cell carcinoma
Background: Accumulating evidence suggests that aberrant HHLA2 expression is closely implicated not only in tumorigenesis, disease progression, and metastatic spread, but also in the intricate modulation of the tumor immune microenvironment. Nevertheless, the biological functions of HHLA2 and the molecular mechanisms underlying its action in laryngeal squamous cell carcinoma (LSCC) remain unexplored. Materials and methods: HHLA2 expression was systematically assessed in LSCC tumor specimens and matched adjacent tissues using multiplex immunofluorescence (mIHC). The functional consequences of HHLA2 silencing in LSCC cells were evaluated through a series of in vitro assays, including CCK-8–based proliferation analysis, wound-healing (scratch) assays, and invasion assays. Transcriptomic sequencing integrated with public database mining was subsequently performed to identify key target genes potentially governed by HHLA2 in regulating LSCC biological behavior. Furthermore, Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Set Enrichment Analysis (GSEA) pathway analyses were conducted to delineate the signaling networks and molecular pathways through which HHLA2 might exert its regulatory effects in LSCC. Results: HHLA2 expression was significantly elevated in LSCC tumor tissues, and associated with poor prognosis in patients. Functional experiments revealed that suppression of HHLA2 leads to marked inhibition of LSCC cell proliferation, migration, and invasion, underscoring its essential role in sustaining malignant phenotypes. Mechanistically, we identified potassium channel tetrameric domain 12 (KCTD12) as a pivotal target of HHLA2 in mediating these oncogenic processes. Importantly, forced overexpression of KCTD12 effectively counterbalanced the inhibitory effects induced by HHLA2 depletion, thereby restoring proliferative, migratory, and invasive potential to LSCC cells. Furthermore, pathway enrichment analyses indicated that the TNF—NF-κB signalling pathway might serve as a key conduit through which HHLA2 orchestrated both tumor cell functions and immune regulatory mechanisms. The HHLA2-KCTD12 axis may regulate the phenotype of LSCC cells and reshape the tumor immune microenvironment through the TNF—NF-κB signaling pathway. Conclusions: HHLA2 enhanced the proliferative, migratory, and invasive capacities of LSCC cells and might contribute to immune microenvironment remodeling via modulation of TNF—NF-κB signaling through the HHLA2–KCTD12 axis.
- Open Access
- 6 August 2024
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 73 (10) , 1-14
Unlocking the potential of HHLA2: identifying functional immune infiltrating cells in the tumor microenvironment and predicting clinical outcomes in laryngeal squamous cell carcinoma
Background HHLA2 (human endogenous retrovirus-H long terminal repeat-associating protein 2) represents a recently identified member of the B7 immune checkpoint family, characterized by limited expression in normal tissues but notable overexpression in various cancer types. Nevertheless, the precise function and interaction with immune cells remain poorly understood, particularly in laryngeal squamous cell carcinoma (LSCC). This investigation endeavored to elucidate the biological significance of HHLA2 within the tumor microenvironment of human LSCC tissues and delineate the clinical relevance and functional roles of HHLA2 in LSCC pathogenesis. Methods Through multiplexed immunohistochemistry analyses conducted on tissue microarrays sourced from LSCC patients (n = 72), the analysis was executed to assess the expression levels of HHLA2, density and spatial patterns of CD68+HLA-DR+CD163− (M1 macrophages), CTLA-4+CD4+FoxP3+ (CTLA-4+Treg cells), CTLA-4+CD4+FoxP3− (CTLA-4+Tcon cells), exhausted CD8+T cells, and terminally exhausted CD8+T cells in LSCC tissues. Survival analysis was conducted to evaluate the prognostic significance of HHLA2 and these immune checkpoints or immune cell populations, employing COX regression analysis to identify independent prognostic factors. Results Kaplan–Meier (K–M) survival curves revealed a significant association between HHLA2 expression and overall survival (OS) in LSCC. Elevated levels of HHLA2 were linked to reduced patient survival, indicating its potential as a prognostic marker (HR: 3.230, 95%CI 0.9205–11.34, P = 0.0067). Notably, increased infiltration of CD68+ cells (total macrophages), STING+CD68+HLA-DR+CD163− (STING+M1 macrophages), CTLA-4+CD4+FoxP3+, CTLA-4+CD4+FoxP3−, PD-1+LAG-3+CD8+T cells, and PD-1+LAG-3+TIM-3+CD8+T cells strongly linked to poorer survival outcomes (P < 0.05). A discernible trend was observed between the levels of these immune cell populations, STING+CD68+ (STING+ total macrophages), CD68+HLA-DR+CD163−, STING+CD68+CD163+HLA-DR− (STING+M2 macrophages), PD-1+LAG-3−CD8+T cells, PD-1+TIM-3+CD8+T cells, and PD-1+LAG-3+TIM-3−CD8+T cells and prognosis. Importantly, multivariate COX analysis identified HHLA2 as an independent predictive factor for OS in LSCC patients (HR = 3.86, 95% CI 1.08–13.80, P = 0.038). This underscored the potential of HHLA2 as a critical marker for predicting patient outcomes in LSCC. Conclusions HHLA2 emerged as a detrimental prognostic biomarker for assessing OS in LSCC patients. Relative to other immune checkpoints, HHLA2 exhibited heightened predictive efficacy for the prognosis of LSCC patients.
- 6 August 2024
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 73 (10) , 1-14
Open AccessUnlocking the potential of HHLA2: identifying functional immune infiltrating cells in the tumor microenvironment and predicting clinical outcomes in laryngeal squamous cell carcinoma
Background HHLA2 (human endogenous retrovirus-H long terminal repeat-associating protein 2) represents a recently identified member of the B7 immune checkpoint family, characterized by limited expression in normal tissues but notable overexpression in various cancer types. Nevertheless, the precise function and interaction with immune cells remain poorly understood, particularly in laryngeal squamous cell carcinoma (LSCC). This investigation endeavored to elucidate the biological significance of HHLA2 within the tumor microenvironment of human LSCC tissues and delineate the clinical relevance and functional roles of HHLA2 in LSCC pathogenesis. Methods Through multiplexed immunohistochemistry analyses conducted on tissue microarrays sourced from LSCC patients (n = 72), the analysis was executed to assess the expression levels of HHLA2, density and spatial patterns of CD68+HLA-DR+CD163− (M1 macrophages), CTLA-4+CD4+FoxP3+ (CTLA-4+Treg cells), CTLA-4+CD4+FoxP3− (CTLA-4+Tcon cells), exhausted CD8+T cells, and terminally exhausted CD8+T cells in LSCC tissues. Survival analysis was conducted to evaluate the prognostic significance of HHLA2 and these immune checkpoints or immune cell populations, employing COX regression analysis to identify independent prognostic factors. Results Kaplan–Meier (K–M) survival curves revealed a significant association between HHLA2 expression and overall survival (OS) in LSCC. Elevated levels of HHLA2 were linked to reduced patient survival, indicating its potential as a prognostic marker (HR: 3.230, 95%CI 0.9205–11.34, P = 0.0067). Notably, increased infiltration of CD68+ cells (total macrophages), STING+CD68+HLA-DR+CD163− (STING+M1 macrophages), CTLA-4+CD4+FoxP3+, CTLA-4+CD4+FoxP3−, PD-1+LAG-3+CD8+T cells, and PD-1+LAG-3+TIM-3+CD8+T cells strongly linked to poorer survival outcomes (P < 0.05). A discernible trend was observed between the levels of these immune cell populations, STING+CD68+ (STING+ total macrophages), CD68+HLA-DR+CD163−, STING+CD68+CD163+HLA-DR− (STING+M2 macrophages), PD-1+LAG-3−CD8+T cells, PD-1+TIM-3+CD8+T cells, and PD-1+LAG-3+TIM-3−CD8+T cells and prognosis. Importantly, multivariate COX analysis identified HHLA2 as an independent predictive factor for OS in LSCC patients (HR = 3.86, 95% CI 1.08–13.80, P = 0.038). This underscored the potential of HHLA2 as a critical marker for predicting patient outcomes in LSCC. Conclusions HHLA2 emerged as a detrimental prognostic biomarker for assessing OS in LSCC patients. Relative to other immune checkpoints, HHLA2 exhibited heightened predictive efficacy for the prognosis of LSCC patients.